{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:16:58Z","timestamp":1740107818203,"version":"3.37.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T00:00:00Z","timestamp":1584748800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T00:00:00Z","timestamp":1584748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s10147-020-01657-2","type":"journal-article","created":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T15:02:45Z","timestamp":1584802965000},"page":"1285-1290","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9115-742X","authenticated-orcid":false,"given":"Yoshihiko","family":"Nakamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Noda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuichi","family":"Mikami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiko","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Okumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadayuki","family":"Doi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiro","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,21]]},"reference":[{"key":"1657_CR1","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/annonc\/mdw206","volume":"27","author":"K Yamazaki","year":"2016","unstructured":"Yamazaki K, Nagase M, Tamagawa H et al (2016) Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol 27:1539\u20131546","journal-title":"Ann Oncol"},{"key":"1657_CR2","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1517\/14656566.2012.709234","volume":"13","author":"T Satoh","year":"2012","unstructured":"Satoh T, Sakata Y (2012) S-1 for the treatment of gastrointestinal cancer. Expert Opin Pharmacother 13:1943\u20131959","journal-title":"Expert Opin Pharmacother"},{"key":"1657_CR3","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S1470-2045(13)70490-X","volume":"14","author":"Y Yamada","year":"2013","unstructured":"Yamada Y, Takahari D, Matsumoto H et al (2013) Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 14:1278\u20131286","journal-title":"Lancet Oncol"},{"key":"1657_CR4","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1470-2045(10)70181-9","volume":"11","author":"K Muro","year":"2010","unstructured":"Muro K, Boku N, Shimada Y et al (2010) Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2\/3 noninferiority study (FIRIS study). Lancet Oncol 11:853\u2013860","journal-title":"Lancet Oncol"},{"key":"1657_CR5","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1093\/annonc\/mds236","volume":"23","author":"HJ Schmoll","year":"2012","unstructured":"Schmoll HJ, Van Cutsem E, Stein A et al (2012) ESMO Consensus Guidelines for management of patients with colon and rectal cancer: a personalized approach to clinical decision making. Ann Oncol 23:2479\u20132516","journal-title":"Ann Oncol"},{"key":"1657_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","volume":"22","author":"C Tournigand","year":"2004","unstructured":"Tournigand C, Andr\u00e9 T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229\u2013237","journal-title":"J Clin Oncol"},{"key":"1657_CR7","doi-asserted-by":"publisher","first-page":"4779","DOI":"10.1200\/JCO.2007.11.3357","volume":"25","author":"CS Fuchs","year":"2007","unstructured":"Fuchs CS, Marshall J, Mitchell E et al (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol 25:4779\u20134786","journal-title":"J Clin Oncol"},{"key":"1657_CR8","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","volume":"26","author":"J Cassidy","year":"2008","unstructured":"Cassidy J, Clarke S, Diaz-Rubio E et al (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006\u20132012","journal-title":"J Clin Oncol"},{"key":"1657_CR9","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","volume":"371","author":"F Loupakis","year":"2014","unstructured":"Loupakis F, Cremolini C, Masi G et al (2014) Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 371:1609\u20131618","journal-title":"N Engl J Med"},{"key":"1657_CR10","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","volume":"15","author":"V Heinemann","year":"2014","unstructured":"Heinemann V, von Weikersthal FL, Decker T et al (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15:1065\u20131075","journal-title":"Lancet Oncol"},{"issue":"Suppl 15","key":"1657_CR11","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1200\/JCO.2016.34.15_suppl.3504","volume":"34","author":"AP Venook","year":"2016","unstructured":"Venook AP, Niedzwiecki D, Innocenti F et al (2016) Impact of primary (1\u00b0) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB\/SWOG 80405 (Alliance). J Clin Oncol 34(Suppl 15):3504","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"1657_CR12","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1200\/JCO.2017.35.15_suppl.3503","volume":"35","author":"AP Venook","year":"2017","unstructured":"Venook AP, Ou FS, Lenz HJ et al (2017) Impact of primary (1\u00b0) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB\/SWOG 80405 (Alliance). J Clin Oncol 35(Suppl 15):3503","journal-title":"J Clin Oncol"},{"key":"1657_CR13","doi-asserted-by":"publisher","first-page":"867","DOI":"10.3109\/0284186X.2012.682629","volume":"51","author":"Y Komatsu","year":"2012","unstructured":"Komatsu Y, Yuki S, Sogabe S et al (2012) Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. Acta Oncol 51:867\u2013872","journal-title":"Acta Oncol"},{"key":"1657_CR14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/FPC.0b013e328014341f","volume":"17","author":"H Minami","year":"2007","unstructured":"Minami H, Sai K, Saeki M et al (2007) Irinotecan pharmacokinetics\/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics 17:497\u2013504","journal-title":"Pharmacogenet Genomics"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01657-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-020-01657-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01657-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,21]],"date-time":"2021-03-21T00:31:44Z","timestamp":1616286704000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-020-01657-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,21]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["1657"],"URL":"https:\/\/doi.org\/10.1007\/s10147-020-01657-2","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"type":"print","value":"1341-9625"},{"type":"electronic","value":"1437-7772"}],"subject":[],"published":{"date-parts":[[2020,3,21]]},"assertion":[{"value":"4 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"N. Tomita has received research funding from Taiho Pharmaceutical Co., Ltd and Chugai Pharmaceutical Co., Ltd. All other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}